Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This book explains the importance and practice of pediatric drug testing for pharmaceutical and toxicology professionals. It describes the practical and ethical issues regarding non-clinical testing to meet US FDA Guidelines, differences resulting from the new European EMEA legislation, and how to develop appropriate information for submission to both agencies. It also provides practical study designs and approaches that can be used to meet international requirements. Covering the full scope of non-clinical testing, regulations, models, practice, and relation to clinical trials, this text offers a comprehensive and up-to-date resource.…mehr
This book explains the importance and practice of pediatric drug testing for pharmaceutical and toxicology professionals. It describes the practical and ethical issues regarding non-clinical testing to meet US FDA Guidelines, differences resulting from the new European EMEA legislation, and how to develop appropriate information for submission to both agencies. It also provides practical study designs and approaches that can be used to meet international requirements. Covering the full scope of non-clinical testing, regulations, models, practice, and relation to clinical trials, this text offers a comprehensive and up-to-date resource.
ALAN M. HOBERMAN, PhD, DABT, Fellow ATS, is Executive Director of Site Operations and Toxicology at Charles River Preclinical Services, Horsham, PA.
ELISE M. LEWIS, PhD, is Director of Reproductive and Neurobehavioral Toxicology at Charles River Preclinical Services, Horsham, PA.
Inhaltsangabe
Preface ix
Acknowledgments xi
Contributors xiii
1. Introduction 1 Elise M. Lewis, Luc M. De Schaepdrijver, and Timothy P. Coogan
2. Overview of Pediatric Diseases and Clinical Considerations on Developing Medicines for Children 29 Bert Suys and Jose Ramet
3. Nonclinical Safety Assessment for Biopharmaceuticals: Challenges and Strategies for Juvenile Animal Testing 41 Timothy P. Coogan
4. FDA Approach to Pediatric Testing 59 Robert E. Osterberg
5. Pediatric Drug Development Plans 79 Kimberly C. Brannen and Beatriz Silva Lima
6. Application of Principles of Nonclinical Pediatric Drug Testing to the Hazard Evaluation of Environmental Contaminants 93 Susan L. Makris
7. Nonclinical Testing Procedures—Pharmacokinetics 115 Loeckie L. de Zwart, Johan G. Monbaliu, and Pieter P. Annaert
8. Preclinical Development of a Pharmaceutical Product for Children 129 Graham P. Bailey, Timothy P. Coogan, and Luc M. De Schaepdrijver
9. Juvenile Toxicity Study Design for the Rodent and Rabbit 141 Alan M. Hoberman and John F. Barnett
10. Dog Juvenile Toxicity 183 Keith Robinson, Susan Y. Smith, and Andre Viau
11. Use of the Swine Pediatric Model 213 Paul C. Barrow
12. Juvenile Immunodevelopment in Minipigs 231 Andr´e H. Penninks, Geertje J.D. van Mierlo, Frieke Kuper, Cor J. Snel, Niels-Christian Ganderup, and Andr´e P.M. Wolterbeek
13. Use of Primate Pediatric Model 255 Gerhard F. Weinbauer, Gary J. Chellman, Allan Dahl Rasmussen and Elvira Vogelwedde
14. Approaches to Rat Juvenile Toxicity Studies and Case Studies: a Pharmaceutical Perspective 281 Susan B. Laffan and Lorraine Posobiec
Appendix 1 Maturation of Organ Systems in Various Species 301
1. Introduction 1 Elise M. Lewis, Luc M. De Schaepdrijver, and Timothy P. Coogan
2. Overview of Pediatric Diseases and Clinical Considerations on Developing Medicines for Children 29 Bert Suys and Jose Ramet
3. Nonclinical Safety Assessment for Biopharmaceuticals: Challenges and Strategies for Juvenile Animal Testing 41 Timothy P. Coogan
4. FDA Approach to Pediatric Testing 59 Robert E. Osterberg
5. Pediatric Drug Development Plans 79 Kimberly C. Brannen and Beatriz Silva Lima
6. Application of Principles of Nonclinical Pediatric Drug Testing to the Hazard Evaluation of Environmental Contaminants 93 Susan L. Makris
7. Nonclinical Testing Procedures—Pharmacokinetics 115 Loeckie L. de Zwart, Johan G. Monbaliu, and Pieter P. Annaert
8. Preclinical Development of a Pharmaceutical Product for Children 129 Graham P. Bailey, Timothy P. Coogan, and Luc M. De Schaepdrijver
9. Juvenile Toxicity Study Design for the Rodent and Rabbit 141 Alan M. Hoberman and John F. Barnett
10. Dog Juvenile Toxicity 183 Keith Robinson, Susan Y. Smith, and Andre Viau
11. Use of the Swine Pediatric Model 213 Paul C. Barrow
12. Juvenile Immunodevelopment in Minipigs 231 Andr´e H. Penninks, Geertje J.D. van Mierlo, Frieke Kuper, Cor J. Snel, Niels-Christian Ganderup, and Andr´e P.M. Wolterbeek
13. Use of Primate Pediatric Model 255 Gerhard F. Weinbauer, Gary J. Chellman, Allan Dahl Rasmussen and Elvira Vogelwedde
14. Approaches to Rat Juvenile Toxicity Studies and Case Studies: a Pharmaceutical Perspective 281 Susan B. Laffan and Lorraine Posobiec
Appendix 1 Maturation of Organ Systems in Various Species 301
